Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings (2014)
- Authors:
- USP affiliated author: PEREIRA, JULIANA - FM
- School: FM
- Subjects: LINFOMA (CLASSIFICAÇÃO); SOBREVIDA; TESTES SOROLÓGICOS; IMUNOHISTOQUÍMICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, suppl, 2014
- Conference title: Annual Meeting and Exposition / ASH
-
ABNT
MACIEL, Felipe V. Rodrigues; SZOR, Roberta S.; LEVY, Debora; SANTUCCI, Rodrigo; PEREIRA, Juliana. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood[S.l: s.n.], 2014. -
APA
Maciel, F. V. R., Szor, R. S., Levy, D., Santucci, R., & Pereira, J. (2014). Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood. New York. -
NLM
Maciel FVR, Szor RS, Levy D, Santucci R, Pereira J. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood. 2014 ; 124( 21): -
Vancouver
Maciel FVR, Szor RS, Levy D, Santucci R, Pereira J. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood. 2014 ; 124( 21): - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- Clinical prognostic models in diffuse large B cell lymphoma patients are still essencial in the rituximab era
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
